Back to Back Issues Page
Less Frequent Eye Injections with Positive Results
August 12, 2020
Hello

Less Frequent Eye Injections with Positive Results

What if you could get the same results of managing your wet macular degeneration with only two eye injections per year? The latest reports from the phase III Archway study sponsored by the drug company La Roche, reports that their port delivery system, a refillable eye implant, can effectively deliver the anti-VEGF drug, ranibizumab (Lucentis) over a period of months. About the size of a grain of rice, the implant is refilled every 6 months.



The reported results of this wet macular degeneration research states, "Refilled every six months, the port delivery system demonstrated non-inferior and equivalent efficacy compared to the standard of care – monthly ranibizumab eye injections – for people with neovascular (wet) age-related macular degeneration."

From anticipating and enduring this uncomfortable procedure to difficulty getting to and from the eye doctor's office, frequent eye injections can be a burden for many patients and their families. The possibility of getting the same benefits with only two eye injections per year would be a welcome change.

Find out more about this macular degeneration research and how it will impact your quality of life while maintaining the benefits of regular eye injections:

Port Delivery System for Sustained Drug Release

Leslie Degner, RN, BSN

Better Health for Better Vision

www.WebRN-MacularDegeneration.com

Back to Back Issues Page